waypoint wealth counsel grew its position in iCAD, Inc. (NASDAQ:ICAD – Free Report) by 44.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,400 shares of the technology company’s stock after buying an additional 4,400 shares during the quarter. waypoint wealth counsel owned 0.05% of iCAD worth $26,000 at the end of the most recent quarter.
Separately, Essex LLC acquired a new stake in iCAD during the 3rd quarter valued at $216,000. Institutional investors own 24.61% of the company’s stock.
iCAD Price Performance
Shares of ICAD opened at $2.42 on Monday. iCAD, Inc. has a 1 year low of $1.18 and a 1 year high of $2.65. The company’s 50 day simple moving average is $1.86 and its 200 day simple moving average is $1.68.
Analyst Ratings Changes
Check Out Our Latest Report on ICAD
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
- Five stocks we like better than iCAD
- How is Compound Interest Calculated?
- D-Wave: Recent Updates Propel Shares Off 2025 Lows
- 3 Fintech Stocks With Good 2021 Prospects
- Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound
- Retail Stocks Investing, Explained
- How the $500 Billion Stargate Investment Can Boost These Stocks
Want to see what other hedge funds are holding ICAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iCAD, Inc. (NASDAQ:ICAD – Free Report).
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
